{"id":783706,"date":"2023-09-13T07:50:28","date_gmt":"2023-09-13T11:50:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/"},"modified":"2023-09-13T07:50:28","modified_gmt":"2023-09-13T11:50:28","slug":"adaptive-announces-launch-of-epic-integration-for-clonoseq","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/","title":{"rendered":"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae"},"content":{"rendered":"

\nThe Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers
\n<\/h2>\n
\n

SEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ\u00ae<\/sup> is now available to health care providers as a fully integrated test in Aura, Epic\u2019s specialty diagnostics suite. This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care.<\/p>\n

MRD refers to the number of cancer cells that might remain in a patient\u2019s body during and after treatment and that may eventually lead to recurrence of the disease. clonoSEQ is the only FDA-cleared test to detect MRD in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). MRD is one of the strongest predictors of outcomes in blood cancers and routine testing provides a personalized way to track a patient\u2019s individual response to treatment and inform clinical decision-making to optimize care.<\/p>\n

\u201cPartnering with Epic, a top EHR provider in the U.S., is an integral part of our vision for a best-in-class customer experience and will accelerate adoption of the test by removing workflow-related barriers that send-out tests commonly face,\u201d said Susan Bobulsky, senior vice president, diagnostics, Adaptive Biotechnologies. \u201cBased on positive feedback from our earliest adopters, and significant interest conveyed by other sites, we will advance our nationwide deployment efforts in order to provide a seamlessly integrated testing experience in Epic for as many providers and patients as possible.\u201d<\/p>\n

Under the partnership established in September 2022, clonoSEQ is available to healthcare providers through Aura, Epic’s specialty diagnostics suite. Integration with Epic EHR provides convenient access to clonoSEQ MRD results along with discrete data directly in patient records, enabling faster, more efficient decision-making for oncologists and equipping patients with real-time insights into their disease status.<\/p>\n

\u201cA clear understanding of MRD status can provide valuable information throughout the care journey \u2013 for patients and physicians alike,\u201d said Flora Stondell, FNP-C, nurse practitioner supervisor, division of malignant hematology\/cellular therapy and transplantation, UC Davis Comprehensive Cancer Center. \u201cIntegrating clonoSEQ into UC Davis\u2019 EHR system will reduce administrative time and further enable personalization of care based on MRD status and treatment response.\u201d<\/p>\n

\u201cCollaboration between providers and diagnostics labs is critical to the advancement of personalized medicine,\u201d said Alan Hutchison, vice president at Epic. \u201cBy making clonoSEQ available through Aura, Adaptive is helping providers incorporate discrete MRD test results into their clinical decision-making, which will have a significant impact on blood cancer patient care.\u201d<\/p>\n

Adaptive and Epic will continue to expand institutional access to clonoSEQ through Epic\u2019s EHR on an ongoing basis. Practices that wish to access clonoSEQ MRD testing directly via Epic should contact their Adaptive account representative or Adaptive\u2019s Account Operations team at clonoSEQAccountOps@adaptivebiotech.com.<\/p>\n

\n About clonoSEQ <\/strong>
\n
clonoSEQ\u00ae<\/sup> is the first and only FDA-cleared in vitro<\/em> diagnostic (IVD) test service to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). MRD refers to the small number of cancer cells that can stay in the body during and after treatment.<\/p>\n

clonoSEQ leverages Adaptive Biotechnologies\u2019 proprietary immune medicine platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment. The assay provides standardized, accurate and sensitive measurement of MRD that allows physicians to predict patient outcomes, assess response to therapy over time, monitor patients during remission and predict potential relapse. Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcomes and response to therapy, and clinical outcomes have been shown to be strongly associated with MRD levels measured by clonoSEQ in patients diagnosed with CLL, MM and ALL.\u00a0<\/p>\n

For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visit\u00a0www.clonoSEQ.com\/technical-summary<\/a>.<\/p>\n

\n About Adaptive<\/strong>
\n
Adaptive Biotechnologies\u00a0is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature\u2019s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in our Immune Medicine and Minimal Residual Disease (MRD) businesses. For more information, please visit\u00a0adaptivebiotech.com<\/a>\u00a0and follow us on\u00a0www.twitter.com\/adaptivebiotech<\/a>.<\/p>\n

\n Forward Looking Statements<\/strong>
\n
This press release contains forward-looking statements that are based on management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.<\/p>\n

In some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the\u00a0Securities and Exchange Commission\u00a0from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n

\n MEDIA CONTACT:<\/strong>
\n
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com<\/a><\/p>\n

\n ADAPTIVE INVESTORS:<\/strong>
\n
Karina Calzadilla, Vice President, Investor Relations
201-396-1687<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers SEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ\u00ae is now available to health care providers as a fully integrated test in Aura, Epic\u2019s specialty diagnostics suite. This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care. MRD refers to the number of cancer cells that might remain … <\/p>\n

Continue reading “Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-783706","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAdaptive Announces Launch of Epic Integration for clonoSEQ\u00ae - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers SEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ\u00ae is now available to health care providers as a fully integrated test in Aura, Epic\u2019s specialty diagnostics suite. This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care. MRD refers to the number of cancer cells that might remain … Continue reading "Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-13T11:50:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTI3NyM1ODExNDYzIzIxNzcxODI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae\",\"datePublished\":\"2023-09-13T11:50:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/\"},\"wordCount\":1169,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTI3NyM1ODExNDYzIzIxNzcxODI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/\",\"name\":\"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTI3NyM1ODExNDYzIzIxNzcxODI=\",\"datePublished\":\"2023-09-13T11:50:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTI3NyM1ODExNDYzIzIxNzcxODI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyMTI3NyM1ODExNDYzIzIxNzcxODI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adaptive-announces-launch-of-epic-integration-for-clonoseq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/","og_locale":"en_US","og_type":"article","og_title":"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae - Market Newsdesk","og_description":"The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers SEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ\u00ae is now available to health care providers as a fully integrated test in Aura, Epic\u2019s specialty diagnostics suite. This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care. MRD refers to the number of cancer cells that might remain … Continue reading \"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-13T11:50:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTI3NyM1ODExNDYzIzIxNzcxODI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae","datePublished":"2023-09-13T11:50:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/"},"wordCount":1169,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTI3NyM1ODExNDYzIzIxNzcxODI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/","name":"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTI3NyM1ODExNDYzIzIxNzcxODI=","datePublished":"2023-09-13T11:50:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTI3NyM1ODExNDYzIzIxNzcxODI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTI3NyM1ODExNDYzIzIxNzcxODI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adaptive-announces-launch-of-epic-integration-for-clonoseq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adaptive Announces Launch of Epic Integration for clonoSEQ\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=783706"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783706\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=783706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=783706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=783706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}